OncoMatch/Clinical Trials/NCT04048278

Lidocaine Infusion in Pancreatic Cancer

Is NCT04048278 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Lidocaine Hydrochloride and Saline Solution for for pancreatic cancer.

Early Phase 1RecruitingUniversity of Illinois at ChicagoNCT04048278Data as of May 2026

Treatment: Lidocaine Hydrochloride · Saline Solution for — This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer. A prospective randomized controlled double blinded trial design will be used for the proposed study.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Performance status

ASA 0–3

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

University of Illnois at Chicago · Chicago, Illinois

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify